Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort.
fatty liver disease
liver diseases
metabolic abnormalities
psychiatric disorders
Journal
Acta psychiatrica Scandinavica
ISSN: 1600-0447
Titre abrégé: Acta Psychiatr Scand
Pays: United States
ID NLM: 0370364
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
10
05
2020
revised:
02
09
2020
accepted:
21
09
2020
pubmed:
5
10
2020
medline:
19
8
2021
entrez:
4
10
2020
Statut:
ppublish
Résumé
Non-Alcoholic fatty liver disease (NAFLD) is becoming the most common liver disease in Western populations. While obesity and metabolic abnormalities are highly frequent in bipolar disorders (BD), no studies have been performed to estimate the prevalence of NALFD in individuals with BD. The aim of our study is to estimate the prevalence of NAFLD and to identify the potential associated risk factors in a large sample of BD individuals. Between 2009 and 2019, 1969 BD individuals from the FACE-BD cohort were included. Individuals with liver diseases, Hepatitis B or C, and current alcohol use disorders were excluded from the analyses. A blood sample was drawn from participants. Screening of NAFLD was determined using fatty liver index (FLI). Individuals with FLI> 60 were considered as having NAFLD. The prevalence of NAFDL in this sample was estimated at 28.4%. NAFLD was observed in 40% of men and 21% of women. NAFLD was independently associated with older age, male gender, sleep disturbances, and current use of atypical antipsychotics or anxiolytics. As expected, the prevalence of NALFD was also higher in individuals with overweight and in those with metabolic syndrome. This study reinforces the view that individuals with BD are highly vulnerable to metabolic and cardiovascular diseases. The prevalence of NAFLD in individuals with BD was two times higher than the prevalence reported in the general population. The regular screening of the MetS in individuals with BD should be therefore complemented by the additional screening of NAFLD among these vulnerable individuals.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-91Investigateurs
B Etain
(B)
C Henry
(C)
E Olié
(E)
M Leboyer
(M)
E Haffen
(E)
P M Llorca
(PM)
V Barteau
(V)
S Bensalem
(S)
O Godin
(O)
H Laouamri
(H)
K Souryis
(K)
S Hotier
(S)
A Pelletier
(A)
N Drancourt
(N)
J P Sanchez
(JP)
E Saliou
(E)
C Hebbache
(C)
J Petrucci
(J)
L Willaume
(L)
E Bourdin
(E)
F Bellivier
(F)
M Carminati
(M)
B Etain
(B)
J Maruani
(J)
E Marlinge
(E)
M Meyrel
(M)
B Antoniol
(B)
A Desage
(A)
S Gard
(S)
A Jutant
(A)
K Mbailara
(K)
I Minois
(I)
L Zanouy
(L)
L Bardin
(L)
A Cazals
(A)
P Courtet
(P)
B Deffinis
(B)
D Ducasse
(D)
M Gachet
(M)
A Henrion
(A)
F Molière
(F)
B Noisette
(B)
E Olié
(E)
G Tarquini
(G)
R Belzeaux
(R)
N Correard
(N)
F Groppi
(F)
A Lefrere
(A)
L Lescalier
(L)
E Moreau
(E)
J Pastol
(J)
M Rebattu
(M)
B Roux
(B)
N Viglianese
(N)
R Cohen
(R)
Raymund Schwan
(R)
J P Kahn
(JP)
M Milazzo
(M)
O Wajsbrot-Elgrabli
(O)
T Bougerol
(T)
B Fredembach
(B)
A Suisse
(A)
B Halili
(B)
A Pouchon
(A)
M Polosan
(M)
A M Galliot
(AM)
I Grévin
(I)
A S Cannavo
(AS)
N Kayser
(N)
C Passerieux
(C)
P Roux
(P)
V Aubin
(V)
I Cussac
(I)
M A Dupont
(MA)
J Loftus
(J)
I Medecin
(I)
C Dubertret
(C)
N Mazer
(N)
C Portalier
(C)
C Scognamiglio
(C)
A Bing
(A)
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543-552.
Management of Physical Health Conditions in Adults with Severe Mental Disorders. World Health Organization; 2018. http://www.ncbi.nlm.nih.gov/books/NBK534487/. Accessed February 11, 2020
Correll CU, Solmi M, Veronese N et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry Off J World Psychiatr Assoc WPA 2017;16:163-180.
Chang C-K, Hayes RD, Perera G et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One 2011;6:e19590.
Vancampfort D, Vansteelandt K, Correll CU et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170:265-274.
Godin O, Etain B, Henry C et al. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry. 2014;75:1078-1085;quiz 1085.
Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20:131-137.
Salvi V, D’Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci. 2011;65:47-54.
Grover S, Mehra A, Chakravarty R, Jagota G, Sahoo S. Change in prevalence of metabolic syndrome in patients with bipolar disorder. Asian J Psychiatry. 2020;47:101876.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol Baltim Md. 2016;64:73-84.
Sarwar R, Pierce N, Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndr Obes Targets Ther. 2018;11:533-542.
Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20.
Bang KB, Cho YK. Comorbidities and metabolic derangement of NAFLD. J Lifestyle Med. 2015;5:7-13.
Henry C, Etain B, Mathieu F et al. A French network of bipolar expert centres: a model to close the gap between evidence-based medicine and routine practice. J Affect Disord. 2011;131:358-363.
First M. Structured clinical interview for the DSM-IV axis I disorders. Am Psychiatr Assoc. 1996. http://www.ncbi.nlm.nih.gov/pubmed/?term=First+AND+1996. Accessed November 21, 2013.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci. 1979;134:382-389.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry J Ment Sci. 1978;133:429-435.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
Bernstein DP, Ahluvalia T, Pogge D, Handelsman L. Validity of the Childhood Trauma Questionnaire in an adolescent psychiatric population. J Am Acad Child Adolesc Psychiatry. 1997;36:340-348.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
Nabi O, Lacombe K, Bousier J, Mathurin P, de Ledinghen V, Goldberg M. Epidemiology of NAFLD and advanced fibrosis in the French general population: a population-based cohort study in 118 664 subjects (NASH-CO study). Hepatology. 2018;68:991.
Vallet-Pichard A, Parlati L, Pol S. Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health. Presse Medicale Paris Fr. 1983;2019:1459-1467.
Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. Neuropsychiatr Dis Treat. 2017;13:1493-1498.
Morlán-Coarasa MJ, Arias-Loste MT, Ortiz-García de la Foz V et al. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology. 2016;233:3947-3952.
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93.
Ijaz S, Bolea B, Davies S et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018;18:275.
Xu H, Zhuang X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatr Dis Treat. 2019;15:2087-2099.
Vancampfort D, Firth J, Schuch F et al. Physical activity and sedentary behavior in people with bipolar disorder: A systematic review and meta-analysis. J Affect Disord. 2016;201:145-152.
Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013;47:197-207.
Nedeltcheva AV, Scheer FAJL. Metabolic effects of sleep disruption, links to obesity and diabetes. Curr Opin Endocrinol Diabetes Obes. 2014;21:293-298.
Kruisbrink M, Robertson W, Ji C, Miller MA, Geleijnse JM, Cappuccio FP. Association of sleep duration and quality with blood lipids: a systematic review and meta-analysis of prospective studies. BMJ Open. 2017;7:e018585.
Mir HM, Stepanova M, Afendy H, Cable R, Younossi ZM. Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): a population-based study. J Clin Exp Hepatol. 2013;3:181-185.
Pulixi EA, Tobaldini E, Battezzati PM et al. Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease. PLoS One 2014;9:e96349.
Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg. 2013;23:1815-1825.
Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev Off J Int Assoc Study Obes. 2013;14:417-431.
Brochard H, Boudebesse C, Henry C, Godin O, Leboyer M, Étain B. [Metabolic syndrome and bipolar disorder: Is sleep the missing link?]. L’Encephale. 2016;42:562-567.
Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016;316:1818-1819.
Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. BioMed Res Int. 2015;2015:1-14.
Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A. Valproic acid and nonalcoholic fatty liver disease: a possible association? World J Hepatol. 2015;7:1251-1257.
Goldstein BI, Baune BT, Bond DJ et al. Call to action regarding the vascular-bipolar link: a report from the Vascular Task Force of the International Society for Bipolar Disorders. Bipolar Disord. 2020;22:440-460.